Novartis AG said it would sell its stake in Roche Holding AG back to its crosstown rival for $20.7 billion, bringing an end to the unusual, decadeslong entanglement of the two Swiss drug giants.
The deal announced Thursday hands Novartis a war chest for potential acquisitions, while for Roche, it removes a major competitor from its shareholder register and will boost earnings per share.
